These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 25520185)

  • 1. Insights into the molecular basis of the NOD2 signalling pathway.
    Boyle JP; Parkhouse R; Monie TP
    Open Biol; 2014 Dec; 4(12):. PubMed ID: 25520185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of human NOD1 and NOD2 NACHT domains reveals different modes of activation.
    Zurek B; Proell M; Wagner RN; Schwarzenbacher R; Kufer TA
    Innate Immun; 2012 Feb; 18(1):100-11. PubMed ID: 21310790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blau syndrome revisited.
    Rose CD; Martin TM; Wouters CH
    Curr Opin Rheumatol; 2011 Sep; 23(5):411-8. PubMed ID: 21788900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases.
    Yao Q
    Semin Arthritis Rheum; 2013 Aug; 43(1):125-30. PubMed ID: 23352252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nod1 and Nod2 in innate immunity and human inflammatory disorders.
    Le Bourhis L; Benko S; Girardin SE
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1479-84. PubMed ID: 18031249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
    Strober W; Asano N; Fuss I; Kitani A; Watanabe T
    Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators.
    Parkhouse R; Boyle JP; Monie TP
    FEBS Lett; 2014 Sep; 588(18):3382-9. PubMed ID: 25093298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOD1 and NOD2 in inflammation, immunity and disease.
    Mukherjee T; Hovingh ES; Foerster EG; Abdel-Nour M; Philpott DJ; Girardin SE
    Arch Biochem Biophys; 2019 Jul; 670():69-81. PubMed ID: 30578751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The present and the prospect of study on Blau syndrome/early-onset sarcoidosis].
    Nakano M; Kambe N
    Nihon Rinsho; 2013 Apr; 71(4):737-41. PubMed ID: 23678609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of NOD1 and NOD2 in host defense against chlamydial infection.
    Zou Y; Lei W; He Z; Li Z
    FEMS Microbiol Lett; 2016 Sep; 363(17):. PubMed ID: 27421958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.
    Dugan J; Griffiths E; Snow P; Rosenzweig H; Lee E; Brown B; Carr DW; Rose C; Rosenbaum J; Davey MP
    J Immunol; 2015 Jan; 194(1):349-57. PubMed ID: 25429073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards an understanding of the role of NOD2/CARD15 in the pathogenesis of Crohn's disease.
    Philpott DJ; Viala J
    Best Pract Res Clin Gastroenterol; 2004 Jun; 18(3):555-68. PubMed ID: 15157827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effect of Arabinosylated lipoarabinomannan restrict the progression of visceral leishmaniasis through NOD2 inflammatory pathway: Functional regulation of T cell subsets.
    Jawed JJ; Banerjee S; Bandyopadhyay S; Parveen S; Chowdhury BP; Saini P; Majumdar S
    Biomed Pharmacother; 2018 Oct; 106():724-732. PubMed ID: 29990864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice.
    Rosenzweig HL; Galster K; Vance EE; Ensign-Lewis J; Nunez G; Davey MP; Rosenbaum JT
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4106-12. PubMed ID: 21296813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases.
    Pashenkov MV; Dagil YA; Pinegin BV
    Int Immunopharmacol; 2018 Jan; 54():385-400. PubMed ID: 29207344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
    Peyrin-Biroulet L; Chamaillard M
    J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOD1 and NOD2: signaling, host defense, and inflammatory disease.
    Caruso R; Warner N; Inohara N; Núñez G
    Immunity; 2014 Dec; 41(6):898-908. PubMed ID: 25526305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The different roles of innate immune receptors in inflammation and carcinogenesis between races.
    Yamaguchi N; Suzuki Y; Mahbub MH; Takahashi H; Hase R; Ishimaru Y; Sunagawa H; Watanabe R; Eishi Y; Tanabe T
    Environ Health Prev Med; 2017 Oct; 22(1):70. PubMed ID: 29165176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands.
    Magalhaes JG; Lee J; Geddes K; Rubino S; Philpott DJ; Girardin SE
    Eur J Immunol; 2011 May; 41(5):1445-55. PubMed ID: 21469090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blau syndrome, the prototypic auto-inflammatory granulomatous disease.
    Wouters CH; Maes A; Foley KP; Bertin J; Rose CD
    Pediatr Rheumatol Online J; 2014; 12():33. PubMed ID: 25136265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.